Sir, -Darhcpoetin alpha .is a novel erythropoiesis stimulating agenL that is e tl'ec tive and safe in maintaining target hemoglo bin concentration at red\lctioD of dose fre quency and at extended dose intervals [Brunkhorst et aI. 2004 , Del Vecchio et al. 2004 , Locatelli et al. 2003]. Tn spite ofthis ev idence and ofthe relev~nt fInancial impact of anemia management, so far few studies has been done,regarding the pharmacoecol1omic impact of Darhepoetin alpha in the manage ment of anemia of uremic patients.
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In order to investigate the effect on Hb and on cost of switching patients from recombi nanL human crythropoietin (rHuEPO) to darbopoetin alpha, we conducted a retrospec tive longitudinal study in three dialysis cen ters in Sicily, Italy, selecting uremic patients· on dialysis treatment who switched from rRuEPO to darbopoerin.
We compared average hemoglobin (Hb) levels and average weekly cost of rHuEPO at the time of switch with those I vels 55 weeks aftcr switching to darbopoetin, using paired sample Ltest.
We compared, in the hospital perspective, weekly cost of pharmacological treatment of anaemia by multiplying thc weekly quantity of drug used times the price per uniL paid by the hospital.
Twenty-five patients were randomized for Lhis analysis and followed-up for 5 weeks. Their mean age aL enrolment was 66.1 years (SD± 13.5); 15 (60%) were male. At the time of switch, the mean (± SD) hemoglobin level was 10,49 gldl (± 1,75) which increased after 55 weeks Lo a mean of 11.15 gldl (± 1.46), with a significant difference of0.66 g/dl in Hb (95%Cl 0.22 gldl to 1.09 gldl), (paired obser vations t-test = 3.1, p = 0.005). At the time of switch, the mean (± SD) weekly cost of rHuEPO was 93.9 (± 59.8) Euro, which de creased to a mean of64.0 (+ 63.5) Euro, with a significant difference in cost of29.88 Euro per week (95% CI 11.2 Bum to 48.5 E~o) (paired observations t-test =3.3, p = 0.003).
At the end of the study period (after 55th week), in 5/25 (20%) patients Hb decreased, in 2 (8%) patients it remained unchanged and increased in 18 (72%).
In dialysis patients who sWitched fi·om rHuI;:PO to darbopoetin alpha, the latter ther apy proved to be more effective and less costly. A projection on the annual cosL of pharmacological treatment in the rHuEPO period leads to an estimate of approximately 4880 Euro per patient (94 Euro times 52 weeks) and it decreases to a projecLed 3,330 (64 x 52), thus lea~ling to an approximate 30% annual savings of 1,550 Euro per pa tient, corresponding to 38,750 Euro for the entire cohort, i.e. approximately the overall annual cost of a dialytic patient. Moreover it is in our opinion thatthe conversion factor be tween darbepOt:tin alpha and rHuEpo is mod ifiable, with furLher reduction of dose, possi bly leading to a further increa e in avings in favor of patients, providers and the society.
